GI Innovation aims to go public on the Kosdaq market in the second half of the year.
Yuhan’s YH35324 allergy treatment candidate won approval for Phase 1 clinical trials in Korea, the pharmaceutical company said Monday.
Korea JoongAng Daily Sitemap
